The Association between Serum Lipids and Intraocular Pressure in 2 Large United Kingdom Cohorts

Modifiable Risk Factors for Glaucoma Collaboration and the UK Biobank Eye and Vision Consortium

doi:10.1016/j.ophtha.2022.04.023

The Association between Serum Lipids and Intraocular Pressure in 2 Large United Kingdom Cohorts

Modifiable Risk Factors for Glaucoma Collaboration and the UK Biobank Eye and Vision Consortium

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Purpose: Serum lipids are modifiable, routinely collected blood test features associated with cardiovascular health. We examined the association of commonly collected serum lipid measures (total cholesterol [TC], high-density lipoprotein cholesterol [HDL-C], low-density lipoprotein cholesterol [LDL-C], and triglycerides) with intraocular pressure (IOP). Design: Cross-sectional study in the UK Biobank and European Prospective Investigation into Cancer and Nutrition (EPIC)-Norfolk cohorts. Participants: We included 94 323 participants from the UK Biobank (mean age, 57 years) and 6230 participants from the EPIC-Norfolk (mean age, 68 years) cohorts with data on TC, HDL-C, LDL-C, and triglycerides collected between 2006 and 2009. Methods: Multivariate linear regression adjusting for demographic, lifestyle, anthropometric, medical, and ophthalmic covariables was used to examine the associations of serum lipids with corneal-compensated IOP (IOPcc). Main Outcome Measures: Corneal-compensated IOP. Results: Higher levels of TC, HDL-C, and LDL-C were associated independently with higher IOPcc in both cohorts after adjustment for key demographic, medical, and lifestyle factors. For each 1-standard deviation increase in TC, HDL-C, and LDL-C, IOPcc was higher by 0.09 mmHg (95% confidence interval [CI], 0.06–0.11 mmHg; P < 0.001), 0.11 mmHg (95% CI, 0.08–0.13 mmHg; P < 0.001), and 0.07 mmHg (95% CI, 0.05–0.09 mmHg; P < 0.001), respectively, in the UK Biobank cohort. In the EPIC-Norfolk cohort, each 1-standard deviation increase in TC, HDL-C, and LDL-C was associated with a higher IOPcc by 0.19 mmHg (95% CI, 0.07–0.31 mmHg; P = 0.001), 0.14 mmHg (95% CI, 0.03–0.25 mmHg; P = 0.016), and 0.17 mmHg (95% CI, 0.06–0.29 mmHg; P = 0.003). An inverse association between triglyceride levels and IOP in the UK Biobank (–0.05 mmHg; 95% CI, –0.08 to –0.03; P < 0.001) was not replicated in the EPIC-Norfolk cohort (P = 0.30). Conclusions: Our findings suggest that serum TC, HDL-C, and LDL-C are associated positively with IOP in 2 United Kingdom cohorts and that triglyceride levels may be associated negatively. Future research is required to assess whether these associations are causal in nature.

Original language	English
Pages (from-to)	986-996
Number of pages	11
Journal	Ophthalmology
Volume	129
Issue number	9
Early online date	2022
DOIs	https://doi.org/10.1016/j.ophtha.2022.04.023
Publication status	Published - Sept 2022

Access to Document

10.1016/j.ophtha.2022.04.023

Cite this

@article{c7d52a7c469043c698b3f8d4536644b2,

title = "The Association between Serum Lipids and Intraocular Pressure in 2 Large United Kingdom Cohorts",

abstract = "Purpose: Serum lipids are modifiable, routinely collected blood test features associated with cardiovascular health. We examined the association of commonly collected serum lipid measures (total cholesterol [TC], high-density lipoprotein cholesterol [HDL-C], low-density lipoprotein cholesterol [LDL-C], and triglycerides) with intraocular pressure (IOP). Design: Cross-sectional study in the UK Biobank and European Prospective Investigation into Cancer and Nutrition (EPIC)-Norfolk cohorts. Participants: We included 94 323 participants from the UK Biobank (mean age, 57 years) and 6230 participants from the EPIC-Norfolk (mean age, 68 years) cohorts with data on TC, HDL-C, LDL-C, and triglycerides collected between 2006 and 2009. Methods: Multivariate linear regression adjusting for demographic, lifestyle, anthropometric, medical, and ophthalmic covariables was used to examine the associations of serum lipids with corneal-compensated IOP (IOPcc). Main Outcome Measures: Corneal-compensated IOP. Results: Higher levels of TC, HDL-C, and LDL-C were associated independently with higher IOPcc in both cohorts after adjustment for key demographic, medical, and lifestyle factors. For each 1-standard deviation increase in TC, HDL-C, and LDL-C, IOPcc was higher by 0.09 mmHg (95% confidence interval [CI], 0.06–0.11 mmHg; P < 0.001), 0.11 mmHg (95% CI, 0.08–0.13 mmHg; P < 0.001), and 0.07 mmHg (95% CI, 0.05–0.09 mmHg; P < 0.001), respectively, in the UK Biobank cohort. In the EPIC-Norfolk cohort, each 1-standard deviation increase in TC, HDL-C, and LDL-C was associated with a higher IOPcc by 0.19 mmHg (95% CI, 0.07–0.31 mmHg; P = 0.001), 0.14 mmHg (95% CI, 0.03–0.25 mmHg; P = 0.016), and 0.17 mmHg (95% CI, 0.06–0.29 mmHg; P = 0.003). An inverse association between triglyceride levels and IOP in the UK Biobank (–0.05 mmHg; 95% CI, –0.08 to –0.03; P < 0.001) was not replicated in the EPIC-Norfolk cohort (P = 0.30). Conclusions: Our findings suggest that serum TC, HDL-C, and LDL-C are associated positively with IOP in 2 United Kingdom cohorts and that triglyceride levels may be associated negatively. Future research is required to assess whether these associations are causal in nature.",

keywords = "Cholesterol, Glaucoma, Intraocular pressure, Lipids",

author = "Madjedi, {Kian M.} and Stuart, {Kelsey V.} and {Modifiable Risk Factors for Glaucoma Collaboration and the UK Biobank Eye and Vision Consortium} and Chua, {Sharon Y. L.} and Luben, {Robert N.} and Alasdair Warwick and Pasquale, {Louis R.} and Kang, {Jae H.} and Wiggs, {Janey L.} and Lentjes, {Marleen A. H.} and Hugues Aschard and Naveed Sattar and Foster, {Paul J.} and Khawaja, {Anthony P.} and Mark Chia and Ron Do and Alan Kastner and Jihye Kim and Giovanni Montesano and Denize Atan and Tariq Aslam and Barman, {Sarah A.} and Barrett, {Jenny H.} and Paul Bishop and Peter Blows and Catey Bunce and Carare, {Roxana O.} and Usha Chakravarthy and Michelle Chan and Crabb, {David P.} and Cumberland, {Philippa M.} and Alexander Day and Parul Desai and Bal Dhillon and Dick, {Andrew D.} and Cathy Egan and Sarah Ennis and Paul Foster and Marcus Fruttiger and Gallacher, {John E. J.} and Garway-Heath, {David F.} and Jane Gibson and Dan Gore and Guggenheim, {Jeremy A.} and Hammond, {Chris J.} and Alison Hardcastle and Harding, {Simon P.} and Hogg, {Ruth E.} and Pirro Hysi and Keane, {Pearse A.} and Khaw, {Sir Peng T.} and Gerassimos Lascaratos and Lotery, {Andrew J.} and Tom Macgillivray and Sarah Mackie and Keith Martin and Michelle McGaughey and Bernadette McGuinness and McKay, {Gareth J.} and Martin McKibbin and Danny Mitry and Tony Moore and Morgan, {James E.} and Muthy, {Zaynah A.} and Eoin O'Sullivan and Owen, {Chris G.} and Praveen Patel and Euan Paterson and Tunde Peto and Axel Petzold and Rahi, {Jugnoo S.} and Rudnikca, {Alicja R.} and Jay Self and Sobha Sivaprasad and David Steel and Irene Stratton and Nicholas Strouthidis and Cathie Sudlow and Dhanes Thomas and Emanuele Trucco and Adnan Tufail and Veronique Vitart and Vernon, {Stephen A.} and Viswanathan, {Ananth C.} and Cathy Williams and Katie Williams and Woodside, {Jayne V.} and MaxM. Yates and Jennifer Yip and Yalin Zheng",

note = "Funding Information: Supported by UCL Overseas Research Scholarship (K.V.S.); Fight for Sight, London, United Kingdom (grant no.: 1956A [K.V.S.]); The Desmond Foundation (K.V.S.); the Wellcome Trust (grant no.: 220558/Z/20/Z [A.W.]); Alcon (P.J.F.); United Kingdom Research and Innovation Future Leaders Fellowship (A.P.K.); Moorfields Eye Charity (Springboard Award [R.N.L.] and Career Development Fellowship [A.P.K.]); the National Eye Institute, National Institutes of Health, Bethesda, Maryland (grant nos.: EY015473 [L.R.P.], EY032559 [L.R.P.], [J.L.W.]); Research to Prevent Blindness, Inc., New York, New York (Challenge Grant [L.R.P., J.L.W.]); The Glaucoma Foundation, New York, New York (L.R.P.); Astra Zeneca (N.S.); Boehringer Ingelheim (N.S.); Novartis (N.S.); Roche Diagnostics (N.S.); Association for Research in Vision and Ophthalmology Foundation (David Epstein Award [J.L.W.]); and UK Research and Innovation Future Leaders Fellowship (Medical Research Council grant no.: MR/T040912/1 [A.P.K.]). The authors acknowledge a proportion of their financial support from the United Kingdom Department of Health through an award made by the National Institute for Health Research to Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology for a Biomedical Research Centre for Ophthalmology. This research used data from the UK Biobank Resource under data access request nos. 2112 and 36741. The UK Biobank Eye and Vision Consortium is supported by grants from Moorfields Eye Charity, The NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, the Alcon Research Institute, and the International Glaucoma Association (United Kingdom). The EPIC-Norfolk study was supported by the Medical Research Council, United Kingdom (grant nos.: SP2024/0201 and MR/N003284/1), and Cancer Research United Kingdom (grant nos.: G9502233 and C864/A8257). No funders had a direct role in the collection, management, analysis, or interpretation of the data; preparation, review, or approval of the manuscript; or in the decision to submit the manuscript for publication. Obtained funding: N/A; Study was performed as part of the authors' regular employment duties. No additional funding was provided. Funding Information: Supported by UCL Overseas Research Scholarship (K.V.S.); Fight for Sight , London, United Kingdom (grant no.: 1956A [K.V.S.]); The Desmond Foundation (K.V.S.); the Wellcome Trust (grant no.: 220558/Z/20/Z [A.W.]); Alcon (P.J.F.); United Kingdom Research and Innovation Future Leaders Fellowship (A.P.K.); Moorfields Eye Charity (Springboard Award [R.N.L.] and Career Development Fellowship [A.P.K.]); the National Eye Institute, National Institutes of Health , Bethesda, Maryland (grant nos.: EY015473 [L.R.P.], EY032559 [L.R.P.], [J.L.W.]); Research to Prevent Blindness , Inc., New York, New York (Challenge Grant [L.R.P., J.L.W.]); The Glaucoma Foundation , New York, New York (L.R.P.); Astra Zeneca (N.S.); Boehringer Ingelheim (N.S.); Novartis (N.S.); Roche Diagnostics (N.S.); Association for Research in Vision and Ophthalmology Foundation (David Epstein Award [J.L.W.]); and UK Research and Innovation Future Leaders Fellowship ( Medical Research Council grant no.: MR/T040912/1 [A.P.K.]). The authors acknowledge a proportion of their financial support from the United Kingdom Department of Health through an award made by the National Institute for Health Research to Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology for a Biomedical Research Centre for Ophthalmology. This research used data from the UK Biobank Resource under data access request nos. 2112 and 36741. The UK Biobank Eye and Vision Consortium is supported by grants from Moorfields Eye Charity, The NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, the Alcon Research Institute , and the International Glaucoma Association (United Kingdom). The EPIC-Norfolk study was supported by the Medical Research Council , United Kingdom (grant nos.: SP2024/0201 and MR/N003284/1 ), and Cancer Research United Kingdom (grant nos.: G9502233 and C864/A8257 ). No funders had a direct role in the collection, management, analysis, or interpretation of the data; preparation, review, or approval of the manuscript; or in the decision to submit the manuscript for publication. Publisher Copyright: {\textcopyright} 2022 American Academy of Ophthalmology",

year = "2022",

month = sep,

doi = "10.1016/j.ophtha.2022.04.023",

language = "English",

volume = "129",

pages = "986--996",

journal = "Ophthalmology",

issn = "0161-6420",

publisher = "Elsevier Inc.",

number = "9",

}

TY - JOUR

T1 - The Association between Serum Lipids and Intraocular Pressure in 2 Large United Kingdom Cohorts

AU - Madjedi, Kian M.

AU - Stuart, Kelsey V.

AU - Modifiable Risk Factors for Glaucoma Collaboration and the UK Biobank Eye and Vision Consortium

AU - Chua, Sharon Y. L.

AU - Luben, Robert N.

AU - Warwick, Alasdair

AU - Pasquale, Louis R.

AU - Kang, Jae H.

AU - Wiggs, Janey L.

AU - Lentjes, Marleen A. H.

AU - Aschard, Hugues

AU - Sattar, Naveed

AU - Foster, Paul J.

AU - Khawaja, Anthony P.

AU - Chia, Mark

AU - Do, Ron

AU - Kastner, Alan

AU - Kim, Jihye

AU - Montesano, Giovanni

AU - Atan, Denize

AU - Aslam, Tariq

AU - Barman, Sarah A.

AU - Barrett, Jenny H.

AU - Bishop, Paul

AU - Blows, Peter

AU - Bunce, Catey

AU - Carare, Roxana O.

AU - Chakravarthy, Usha

AU - Chan, Michelle

AU - Crabb, David P.

AU - Cumberland, Philippa M.

AU - Day, Alexander

AU - Desai, Parul

AU - Dhillon, Bal

AU - Dick, Andrew D.

AU - Egan, Cathy

AU - Ennis, Sarah

AU - Foster, Paul

AU - Fruttiger, Marcus

AU - Gallacher, John E. J.

AU - Garway-Heath, David F.

AU - Gibson, Jane

AU - Gore, Dan

AU - Guggenheim, Jeremy A.

AU - Hammond, Chris J.

AU - Hardcastle, Alison

AU - Harding, Simon P.

AU - Hogg, Ruth E.

AU - Hysi, Pirro

AU - Keane, Pearse A.

AU - Khaw, Sir Peng T.

AU - Lascaratos, Gerassimos

AU - Lotery, Andrew J.

AU - Macgillivray, Tom

AU - Mackie, Sarah

AU - Martin, Keith

AU - McGaughey, Michelle

AU - McGuinness, Bernadette

AU - McKay, Gareth J.

AU - McKibbin, Martin

AU - Mitry, Danny

AU - Moore, Tony

AU - Morgan, James E.

AU - Muthy, Zaynah A.

AU - O'Sullivan, Eoin

AU - Owen, Chris G.

AU - Patel, Praveen

AU - Paterson, Euan

AU - Peto, Tunde

AU - Petzold, Axel

AU - Rahi, Jugnoo S.

AU - Rudnikca, Alicja R.

AU - Self, Jay

AU - Sivaprasad, Sobha

AU - Steel, David

AU - Stratton, Irene

AU - Strouthidis, Nicholas

AU - Sudlow, Cathie

AU - Thomas, Dhanes

AU - Trucco, Emanuele

AU - Tufail, Adnan

AU - Vitart, Veronique

AU - Vernon, Stephen A.

AU - Viswanathan, Ananth C.

AU - Williams, Cathy

AU - Williams, Katie

AU - Woodside, Jayne V.

AU - Yates, MaxM.

AU - Yip, Jennifer

AU - Zheng, Yalin

N1 - Funding Information: Supported by UCL Overseas Research Scholarship (K.V.S.); Fight for Sight, London, United Kingdom (grant no.: 1956A [K.V.S.]); The Desmond Foundation (K.V.S.); the Wellcome Trust (grant no.: 220558/Z/20/Z [A.W.]); Alcon (P.J.F.); United Kingdom Research and Innovation Future Leaders Fellowship (A.P.K.); Moorfields Eye Charity (Springboard Award [R.N.L.] and Career Development Fellowship [A.P.K.]); the National Eye Institute, National Institutes of Health, Bethesda, Maryland (grant nos.: EY015473 [L.R.P.], EY032559 [L.R.P.], [J.L.W.]); Research to Prevent Blindness, Inc., New York, New York (Challenge Grant [L.R.P., J.L.W.]); The Glaucoma Foundation, New York, New York (L.R.P.); Astra Zeneca (N.S.); Boehringer Ingelheim (N.S.); Novartis (N.S.); Roche Diagnostics (N.S.); Association for Research in Vision and Ophthalmology Foundation (David Epstein Award [J.L.W.]); and UK Research and Innovation Future Leaders Fellowship (Medical Research Council grant no.: MR/T040912/1 [A.P.K.]). The authors acknowledge a proportion of their financial support from the United Kingdom Department of Health through an award made by the National Institute for Health Research to Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology for a Biomedical Research Centre for Ophthalmology. This research used data from the UK Biobank Resource under data access request nos. 2112 and 36741. The UK Biobank Eye and Vision Consortium is supported by grants from Moorfields Eye Charity, The NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, the Alcon Research Institute, and the International Glaucoma Association (United Kingdom). The EPIC-Norfolk study was supported by the Medical Research Council, United Kingdom (grant nos.: SP2024/0201 and MR/N003284/1), and Cancer Research United Kingdom (grant nos.: G9502233 and C864/A8257). No funders had a direct role in the collection, management, analysis, or interpretation of the data; preparation, review, or approval of the manuscript; or in the decision to submit the manuscript for publication. Obtained funding: N/A; Study was performed as part of the authors' regular employment duties. No additional funding was provided. Funding Information: Supported by UCL Overseas Research Scholarship (K.V.S.); Fight for Sight , London, United Kingdom (grant no.: 1956A [K.V.S.]); The Desmond Foundation (K.V.S.); the Wellcome Trust (grant no.: 220558/Z/20/Z [A.W.]); Alcon (P.J.F.); United Kingdom Research and Innovation Future Leaders Fellowship (A.P.K.); Moorfields Eye Charity (Springboard Award [R.N.L.] and Career Development Fellowship [A.P.K.]); the National Eye Institute, National Institutes of Health , Bethesda, Maryland (grant nos.: EY015473 [L.R.P.], EY032559 [L.R.P.], [J.L.W.]); Research to Prevent Blindness , Inc., New York, New York (Challenge Grant [L.R.P., J.L.W.]); The Glaucoma Foundation , New York, New York (L.R.P.); Astra Zeneca (N.S.); Boehringer Ingelheim (N.S.); Novartis (N.S.); Roche Diagnostics (N.S.); Association for Research in Vision and Ophthalmology Foundation (David Epstein Award [J.L.W.]); and UK Research and Innovation Future Leaders Fellowship ( Medical Research Council grant no.: MR/T040912/1 [A.P.K.]). The authors acknowledge a proportion of their financial support from the United Kingdom Department of Health through an award made by the National Institute for Health Research to Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology for a Biomedical Research Centre for Ophthalmology. This research used data from the UK Biobank Resource under data access request nos. 2112 and 36741. The UK Biobank Eye and Vision Consortium is supported by grants from Moorfields Eye Charity, The NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, the Alcon Research Institute , and the International Glaucoma Association (United Kingdom). The EPIC-Norfolk study was supported by the Medical Research Council , United Kingdom (grant nos.: SP2024/0201 and MR/N003284/1 ), and Cancer Research United Kingdom (grant nos.: G9502233 and C864/A8257 ). No funders had a direct role in the collection, management, analysis, or interpretation of the data; preparation, review, or approval of the manuscript; or in the decision to submit the manuscript for publication. Publisher Copyright: © 2022 American Academy of Ophthalmology

PY - 2022/9

Y1 - 2022/9

N2 - Purpose: Serum lipids are modifiable, routinely collected blood test features associated with cardiovascular health. We examined the association of commonly collected serum lipid measures (total cholesterol [TC], high-density lipoprotein cholesterol [HDL-C], low-density lipoprotein cholesterol [LDL-C], and triglycerides) with intraocular pressure (IOP). Design: Cross-sectional study in the UK Biobank and European Prospective Investigation into Cancer and Nutrition (EPIC)-Norfolk cohorts. Participants: We included 94 323 participants from the UK Biobank (mean age, 57 years) and 6230 participants from the EPIC-Norfolk (mean age, 68 years) cohorts with data on TC, HDL-C, LDL-C, and triglycerides collected between 2006 and 2009. Methods: Multivariate linear regression adjusting for demographic, lifestyle, anthropometric, medical, and ophthalmic covariables was used to examine the associations of serum lipids with corneal-compensated IOP (IOPcc). Main Outcome Measures: Corneal-compensated IOP. Results: Higher levels of TC, HDL-C, and LDL-C were associated independently with higher IOPcc in both cohorts after adjustment for key demographic, medical, and lifestyle factors. For each 1-standard deviation increase in TC, HDL-C, and LDL-C, IOPcc was higher by 0.09 mmHg (95% confidence interval [CI], 0.06–0.11 mmHg; P < 0.001), 0.11 mmHg (95% CI, 0.08–0.13 mmHg; P < 0.001), and 0.07 mmHg (95% CI, 0.05–0.09 mmHg; P < 0.001), respectively, in the UK Biobank cohort. In the EPIC-Norfolk cohort, each 1-standard deviation increase in TC, HDL-C, and LDL-C was associated with a higher IOPcc by 0.19 mmHg (95% CI, 0.07–0.31 mmHg; P = 0.001), 0.14 mmHg (95% CI, 0.03–0.25 mmHg; P = 0.016), and 0.17 mmHg (95% CI, 0.06–0.29 mmHg; P = 0.003). An inverse association between triglyceride levels and IOP in the UK Biobank (–0.05 mmHg; 95% CI, –0.08 to –0.03; P < 0.001) was not replicated in the EPIC-Norfolk cohort (P = 0.30). Conclusions: Our findings suggest that serum TC, HDL-C, and LDL-C are associated positively with IOP in 2 United Kingdom cohorts and that triglyceride levels may be associated negatively. Future research is required to assess whether these associations are causal in nature.

AB - Purpose: Serum lipids are modifiable, routinely collected blood test features associated with cardiovascular health. We examined the association of commonly collected serum lipid measures (total cholesterol [TC], high-density lipoprotein cholesterol [HDL-C], low-density lipoprotein cholesterol [LDL-C], and triglycerides) with intraocular pressure (IOP). Design: Cross-sectional study in the UK Biobank and European Prospective Investigation into Cancer and Nutrition (EPIC)-Norfolk cohorts. Participants: We included 94 323 participants from the UK Biobank (mean age, 57 years) and 6230 participants from the EPIC-Norfolk (mean age, 68 years) cohorts with data on TC, HDL-C, LDL-C, and triglycerides collected between 2006 and 2009. Methods: Multivariate linear regression adjusting for demographic, lifestyle, anthropometric, medical, and ophthalmic covariables was used to examine the associations of serum lipids with corneal-compensated IOP (IOPcc). Main Outcome Measures: Corneal-compensated IOP. Results: Higher levels of TC, HDL-C, and LDL-C were associated independently with higher IOPcc in both cohorts after adjustment for key demographic, medical, and lifestyle factors. For each 1-standard deviation increase in TC, HDL-C, and LDL-C, IOPcc was higher by 0.09 mmHg (95% confidence interval [CI], 0.06–0.11 mmHg; P < 0.001), 0.11 mmHg (95% CI, 0.08–0.13 mmHg; P < 0.001), and 0.07 mmHg (95% CI, 0.05–0.09 mmHg; P < 0.001), respectively, in the UK Biobank cohort. In the EPIC-Norfolk cohort, each 1-standard deviation increase in TC, HDL-C, and LDL-C was associated with a higher IOPcc by 0.19 mmHg (95% CI, 0.07–0.31 mmHg; P = 0.001), 0.14 mmHg (95% CI, 0.03–0.25 mmHg; P = 0.016), and 0.17 mmHg (95% CI, 0.06–0.29 mmHg; P = 0.003). An inverse association between triglyceride levels and IOP in the UK Biobank (–0.05 mmHg; 95% CI, –0.08 to –0.03; P < 0.001) was not replicated in the EPIC-Norfolk cohort (P = 0.30). Conclusions: Our findings suggest that serum TC, HDL-C, and LDL-C are associated positively with IOP in 2 United Kingdom cohorts and that triglyceride levels may be associated negatively. Future research is required to assess whether these associations are causal in nature.

KW - Cholesterol

KW - Glaucoma

KW - Intraocular pressure

KW - Lipids

UR - http://www.scopus.com/inward/record.url?scp=85134782313&partnerID=8YFLogxK

U2 - 10.1016/j.ophtha.2022.04.023

DO - 10.1016/j.ophtha.2022.04.023

M3 - Article

C2 - 35500606

SN - 0161-6420

VL - 129

SP - 986

EP - 996

JO - Ophthalmology

JF - Ophthalmology

IS - 9

ER -

The Association between Serum Lipids and Intraocular Pressure in 2 Large United Kingdom Cohorts

Abstract

Access to Document

Other files and links

Cite this